Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

Active:	Yes
Cancer Type:	Unknown Primary	NCT ID:	NCT07265947
Trial Phases:	Phase II	Protocol IDs:	TYR300-203 (primary) NCI-2026-01135 2025-523539-20-00
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Tyra Biosciences, Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT07265947

Summary

A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial
Carcinoma

Objectives

A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of
Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma
(SURF303)

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.